Breaking Finance News

RBC Capital Markets announced Concordia Healthcare Corp (TSE:CXR), bumping up its stock price target to $18.00 today

Indicating a possible upside of 1.63%, RBC Capital Markets bumped the target stock price of Concordia Healthcare Corp (TSE:CXR) to $18.

On 9/19/2016, TD Securities released a statement on Concordia Healthcare Corp(TSE:CXR) dropped the target price from $14.00 to $7.00. At the time, this indicated a possible upside of 0.04%.

Only yesterday Concordia Healthcare Corp (TSE:CXR) traded 1.48% higher at $6.84. Concordia Healthcare Corp’s 50-day moving average is $13.06 and its 200-day average is $28.33. The last stock price close is down 75.79% from the two hundred day average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the same period. 438,578 shares of CXR traded, down from ann average trading volume of 803,208.

See Graphic Below:

Concordia Healthcare Corp (TSE:CXR)

Concordia Healthcare Corp has a 52 week low of $6.33 and a one-year high of $95.21 and has a total market value of $0.0.

In addition to RBC Capital Markets reporting it’s price target, a total of 10 firms have reported on Concordia Healthcare Corp. The one year target price is $19.46 with 0 rating the stock a strong buy, 0 rating the company a buy, 0 analysts rating the stock a hold, 0 rating the stock to underperform, and finally 0 brokeragesrating the stock as sell.

About Concordia Healthcare Corp (TSE:CXR)

Concordia International Corp, formerly Concordia Healthcare Corp, is a Canada-based pharmaceutical company. The Company, through subsidiaries, owns a portfolio of branded and generic prescription products. Its activities are divided into four segments: Concordia North America, includes sales of pharmaceutical products, such as Donnatal for the treatment of irritable bowel syndrome, Zonegran for the treatment of partial seizures in adults with epilepsy and Nilandron for the treatment of metastatic prostate cancer; Concordia International, includes a portfolio of branded and generic products that are sold to wholesalers, hospitals and pharmacies in over 100 countries, and focuses on acquisition, licensing and development of off-patent prescription medicines; Orphan Drugs, includes Photofrin, which is for the treatment of certain forms of rare cancer, and Corporate cost centre, and includes centralized costs incurred by the Company.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.